Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursodeoxycholic acid to improve vedolizumab efficacy in inflammatory bowel disease
ChiCTR2500104974Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of ursodeoxycholic acid and vedolizumab in autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: safety and tolerability. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
ursodeoxycholic acidvedolizumab
03
Conditions
autoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on ChiCTR2500104974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104974.